2022 Sustainability Report
Extracted ESG KPIs
KPIs are organized by ESG aspects.
The types of emissions and respective emissions data.
| Indicator | Unit | 2021 | 2022 | Report Pages |
|---|---|---|---|---|
| Nitrogen Oxides (NOx) emissions - Consolidated +SHPL | kg | 884 | 819 | 43 |
| Nitrogen Oxides (NOx) emissions - Consolidated Entities (Oncology/Immunology & Subsidiaries) | kg | 5.38 | 24.86 | 43 |
| Particulate Matter (PM) emissions - Consolidated +SHPL | kg | 155 | 128 | 43 |
| Particulate Matter (PM) emissions - Consolidated Entities (Oncology/Immunology & Subsidiaries) | kg | 0.4 | 2.23 | 43 |
| Sulphur Oxides (SOx) emissions - Consolidated +SHPL | kg | 0.45 | 0.38 | 43 |
| Sulphur Oxides (SOx) emissions - Consolidated Entities (Oncology/Immunology & Subsidiaries) | kg | 0.12 | 0.18 | 43 |
Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).
| Indicator | Unit | 2019 | 2020 | 2021 | 2022 | Report Pages |
|---|---|---|---|---|---|---|
| Direct GHG emissions (Scope 1) (Consolidated + SHPL) | tCO2e | 5587 | 40 | |||
| Direct GHG emissions (Scope 1) (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tCO2e | 244 | 40 | |||
| Direct GHG emissions (Scope 1) - Consolidated +SHPL | tCO2e | 6040 | 5169 | 5587 | 43 | |
| Direct GHG emissions (Scope 1) - Consolidated Entities (Oncology/Immunology & Subsidiaries) | tCO2e | 14 | 313 | 244 | 43 | |
| Emissions Data from Business Air Travel (consolidated entities) | kg CO2e | 364542 | 261719 | 522348 | 381919 | 38 |
| GHG (Scope 1 and 2) emission intensity (tCO2e/US$'000 revenue) - Consolidated +SHPL | tCO2e/US$'000 | 0.046 | 0.032 | 0.025 | 43 | |
| GHG (Scope 1 and 2) emission intensity (tCO2e/US$'000 revenue) - Consolidated Entities (Oncology/Immunology & Subsidiaries) | tCO2e/US$'000 | 0.025 | 0.021 | 0.013 | 43 | |
| GHG Emissions Intensity (consolidated entities) | tCO2e / US$000 revenue | 0.025 | 0.022 | 0.013 | 38 | |
| GHG emission intensity (Scope 1 & 2) (Consolidated + SHPL) | tCO2e per US$'000 revenue, tCO2e per employee | 0.025 | 40 | |||
| GHG emission intensity (Scope 1 & 2) (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tCO2e per US$'000 revenue, tCO2e per employee | 0.013 | 40 | |||
| GHG emissions (Scope 1 and 2) - Consolidated +SHPL | tCO2e | 21946 | 21505 | 20106 | 43 | |
| GHG emissions (Scope 1 and 2) - Consolidated Entities (Oncology/Immunology & Subsidiaries) | tCO2e | 5087 | 7029 | 5551 | 43 | |
| Indirect GHG emissions (Scope 2) (Consolidated + SHPL) | tCO2e | 14519 | 40 | |||
| Indirect GHG emissions (Scope 2) (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tCO2e | 5307 | 40 | |||
| Indirect GHG emissions (Scope 2) - Consolidated +SHPL | tCO2e | 19506 | 16336 | 14519 | 43 | |
| Indirect GHG emissions (Scope 2) - Consolidated Entities (Oncology/Immunology & Subsidiaries) | tCO2e | 5073 | 6716 | 5307 | 43 | |
| Other indirect GHG emissions (Scope 3) (Consolidated + SHPL) | tCO2e | 442 | 40 | |||
| Other indirect GHG emissions (Scope 3) (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tCO2e | 382 | 40 | |||
| Other indirect GHG emissions (Scope 3) - Consolidated +SHPL | tCO2e | 410 | 721 | 442 | 43 | |
| Other indirect GHG emissions (Scope 3) - Consolidated Entities (Oncology/Immunology & Subsidiaries) | tCO2e | 262 | 522 | 382 | 43 | |
| Reduction in absolute GHG emissions | compared to 2021 | 21% | 39 | |||
| Reduction of carbon emission intensity from operations compared to 2020 (achieved by end of 2022) | percent | 48 | 6 | |||
| Total emissions (Scope 1) - Consolidated +SHPL | tCO2e | 22356 | 22226 | 20548 | 43 | |
| Total emissions (Scope 1) - Consolidated Entities (Oncology/Immunology & Subsidiaries) | tCO2e | 5349 | 7551 | 5933 | 43 | |
| Total emissions (Scope 1-3) (Consolidated + SHPL) | tCO2e | 20548 | 40 | |||
| Total emissions (Scope 1-3) (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tCO2e | 5933 | 40 | |||
| carbon emission from business air travel (vs 2019) | +5% | 36 | ||||
| carbon emission from business air travel (vs 2021) | -27% | 36 | ||||
| carbon emission intensity | -48% | 36 |
Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).
| Indicator | Unit | 2021 | 2022 | Report Pages |
|---|---|---|---|---|
| Hazardous waste intensity | tons/US$'000 revenue | 0.000186 | 41 | |
| Hazardous waste intensity (Consolidated +SHPL) | tons/US$'000 | 0.000193 | 0.000172 | 45 |
| Hazardous waste intensity (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tons/US$'000 | 0.000186 | 45 | |
| Waste - Hazardous waste (Consolidated +SHPL) | tons | 113 | 137 | 45 |
| Waste - Hazardous waste (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tons | 79 | 45 |
Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).
| Indicator | Unit | 2021 | 2022 | Report Pages |
|---|---|---|---|---|
| Non-hazardous waste generated | tons | 18 | 41 | |
| Non-hazardous waste intensity | tons/US$'000 revenue | 0.00042 | 41 | |
| Non-hazardous waste intensity (Consolidated +SHPL) | tons/US$'000 | 0.000184 | 0.000112 | 45 |
| Non-hazardous waste intensity (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tons/US$'000 | 0.000042 | 45 | |
| Waste - Non-hazardous waste (Consolidated +SHPL) | tons | 108 | 89 | 45 |
| Waste - Non-hazardous waste (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tons | 18 | 45 |
Description of emissions target(s) set and steps taken to achieve them.
| Indicator | Unit | 2022 | 2025 | Report Pages |
|---|---|---|---|---|
| 2025 Environmental Target 1 (Carbon Emission Intensity): Target to reduce 30% of carbon emission intensity by 2025 compared to 2020 | percent (compared to 2020) | -30 | 16 | |
| 2025 Environmental Target 3 (Emission from Business Travel): Target to reduce 10% of emissions from business air travel by 2025 compared to 2019 | percent (compared to 2019) | -10 | 16 | |
| reduction in carbon emissions intensity compared to 2020 | percent | 48 | 3 |
Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.
| Indicator | Unit | 2021 | 2022 | Report Pages |
|---|---|---|---|---|
| Chinese medicine residue and sludge diverted from waste stream for composting | tons | 2400 | 41 | |
| Chinese medicine residue and sludge recycled group-wide | tons | 2400 | 39 | |
| Printer cartridges recycled (Consolidated +SHPL) | pieces | 42 | 142 | 45 |
| Printer cartridges recycled (Consolidated Entities - Oncology/Immunology & Subsidiaries) | pieces | 82 | 45 | |
| Waste recycled by type - Chinese medicine residue (Consolidated +SHPL) | tons | 3468 | 1858 | 45 |
| Waste recycled by type - Metals (Consolidated +SHPL) | tons | 1.23 | 3.9 | 45 |
| Waste recycled by type - Paper (Consolidated +SHPL) | tons | 2.4 | 3.4 | 45 |
| Waste recycled by type - Paper (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tons | 2 | 45 | |
| Waste recycled by type - Plastic (Consolidated +SHPL) | tons | 106 | 20 | 45 |
| Waste recycled by type - Sludge (Consolidated +SHPL) | tons | 479 | 556 | 45 |
| Waste recycled by type - Total (Consolidated +SHPL) | tons | 4165 | 2440 | 45 |
| Waste recycled by type - Total (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tons | 2 | 45 |
Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).
| Indicator | Unit | 2020 | 2021 | 2022 | Report Pages |
|---|---|---|---|---|---|
| Diesel consumption - Consolidated +SHPL | GJ | 2 | 2 | 44 | |
| Electricity consumption - Consolidated +SHPL | GJ | 99883 | 88810 | 44 | |
| Electricity consumption - Consolidated Entities (Oncology/Immunology & Subsidiaries) | GJ | 26025 | 41140 | 32557 | 44 |
| Energy Consumption Intensity (consolidated entities) | GJ / US$000 revenue | 0.128 | 0.124 | 0.077 | 38 |
| Energy consumption (Consolidated + SHPL) | GJ, kWh in '000 | 64076 | 40 | ||
| Energy consumption (Consolidated Entities - Oncology/Immunology & Subsidiaries) | GJ, kWh in '000 | 9163 | 40 | ||
| Energy consumption intensity (Consolidated + SHPL) | GJ per US$'000 revenue | 0.289 | 40 | ||
| Energy consumption intensity (Consolidated Entities - Oncology/Immunology & Subsidiaries) | GJ per US$'000 revenue | 0.077 | 40 | ||
| Gasoline consumption - Consolidated +SHPL | GJ | 1067 | 911 | 44 | |
| Gasoline consumption - Consolidated Entities (Oncology/Immunology & Subsidiaries) | GJ | 182 | 288 | 419 | 44 |
| Natural gas consumption - Consolidated +SHPL | GJ | 124587 | 140942 | 44 | |
| Reduction in absolute electricity consumption | compared to 2021 | 21% | 39 | ||
| Steam consumption - Consolidated +SHPL | GJ | 11 | 10 | 44 | |
| Steam consumption - Consolidated Entities (Oncology/Immunology & Subsidiaries) | GJ | 11 | 11 | 10 | 44 |
| Total Energy Consumption (GJ) - Consolidated +SHPL | GJ | 225549 | 230674 | 44 | |
| Total Energy Consumption (GJ) - Consolidated Entities (Oncology/Immunology & Subsidiaries) | GJ | 26014 | 41439 | 32986 | 44 |
| Total Energy Consumption (kWH'000) - Consolidated +SHPL | kWH'000 | 62653 | 64076 | 44 | |
| Total Energy Consumption (kWH'000) - Consolidated Entities (Oncology/Immunology & Subsidiaries) | kWH'000 | 7282 | 11511 | 9163 | 44 |
| Total energy intensity (GJ/US$'000 revenue) - Consolidated +SHPL | GJ/US$'000 revenue | 0.39 | 0.338 | 0.289 | 44 |
| Total energy intensity (GJ/US$'000 revenue) - Consolidated Entities (Oncology/Immunology & Subsidiaries) | GJ/US$'000 revenue | 0.128 | 0.124 | 0.077 | 44 |
| energy intensity | -40% | 36 |
Water consumption in total and intensity (e.g. per unit of production volume, per facility).
| Indicator | Unit | 2021 | 2022 | Report Pages |
|---|---|---|---|---|
| Decrease in wastewater discharged compared to last year | 15% | 41 | ||
| Wastewater discharged - Consolidated +SHPL | cubic meters | 223534 | 189064 | 44 |
| Wastewater discharged - Consolidated Entities (Oncology/Immunology & Subsidiaries) | cubic meters | 19736 | 44 | |
| Wastewater discharged by the Group | cubic meters | 189064 | 41 | |
| Water consumption - Consolidated +SHPL | cubic meters | 311256 | 270555 | 44 |
| Water consumption - Consolidated Entities (Oncology/Immunology & Subsidiaries) | cubic meters | 22397 | 44 | |
| Water consumption intensity (cubic meters/US$'000 revenue) - Consolidated +SHPL | cubic meters/US$'000 revenue | 0.47 | 0.34 | 44 |
| Water consumption intensity (cubic meters/US$'000 revenue) - Consolidated Entities (Oncology/Immunology & Subsidiaries) | cubic meters/US$'000 revenue | 0.05 | 44 |
Description of energy use efficiency target(s) set and steps taken to achieve them.
| Indicator | Unit | 2022 | 2025 | Report Pages |
|---|---|---|---|---|
| 2025 Environmental Target 2 (Energy Intensity): Target to reduce 10% of energy intensity by 2025 compared to 2020 | percent (compared to 2020) | -10 | 16 | |
| Reduction of energy intensity from operations compared to 2020 (achieved by end of 2022) | percent | 40 | 6 | |
| reduction in energy intensity compared to 2020 | percent | 40 | 3 |
Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.
| Indicator | Unit | 2022 | Report Pages |
|---|---|---|---|
| Total reduction in water consumption across the Group | compared to 2021 | 13% | 39 |
Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.
| Indicator | Unit | 2021 | 2022 | Report Pages |
|---|---|---|---|---|
| Packaging materials used - Metals (Consolidated +SHPL) | tons | 35 | 36 | 45 |
| Packaging materials used - Metals (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tons | 1 | 45 | |
| Packaging materials used - Paper (Consolidated +SHPL) | tons | 1106 | 750 | 45 |
| Packaging materials used - Paper (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tons | 12 | 45 | |
| Packaging materials used - Plastic (Consolidated +SHPL) | tons | 779 | 830 | 45 |
| Packaging materials used - Plastic (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tons | 6 | 45 | |
| Packaging materials used - Total (Consolidated +SHPL) | tons | 1920 | 1616 | 45 |
| Packaging materials used - Total (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tons | 19 | 45 | |
| Total paper purchased (Consolidated +SHPL) | tons | 19 | 83 | 45 |
| Total paper purchased (Consolidated Entities - Oncology/Immunology & Subsidiaries) | tons | 29 | 45 |
Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.
| Indicator | Unit | 2020 | 2021 | 2022 | 2025 | Report Pages |
|---|---|---|---|---|---|---|
| 2025 Social Target 4 (Diversity, equity and inclusion): Target to achieve gender equality for middle management and above | middle management and above | gender equality | 16 | |||
| Employee (Consolidated + SHPL) | person | 5013 | 40 | |||
| Employee (Consolidated Entities - Oncology/Immunology & Subsidiaries) | person | 2027 | 40 | |||
| Target for percentage of women in middle management and above by 2025 | percent | 40 | 6 | |||
| Total number of employees (Consolidated + SHPL) | 4121 | 4598 | 5013 | 71 | ||
| Total number of employees (Oncology/Immunology & Subsidiaries) | 1205 | 1715 | 2027 | 71 | ||
| Total number of employees by age 20-29 (Female) | 88 | 160 | 304 | 71 | ||
| Total number of employees by age 20-29 (Male) | 570 | 152 | 203 | 71 | ||
| Total number of employees by age 30-39 (Female) | 339 | 402 | 539 | 71 | ||
| Total number of employees by age 30-39 (Male) | 1324 | 309 | 475 | 71 | ||
| Total number of employees by age 40-49 (Female) | 136 | 181 | 199 | 71 | ||
| Total number of employees by age 40-49 (Male) | 596 | 108 | 195 | 71 | ||
| Total number of employees by age 50-59 (Female) | 26 | 47 | 49 | 71 | ||
| Total number of employees by age 50-59 (Male) | 77 | 42 | 38 | 71 | ||
| Total number of employees by age 60 and above (Female) | 6 | 7 | 10 | 71 | ||
| Total number of employees by age 60 and above (Male) | 9 | 14 | 15 | 71 | ||
| Total number of employees by contract type - Full-time (Consolidated + SHPL) | 4075 | 4598 | 5011 | 72 | ||
| Total number of employees by contract type - Full-time (Consolidated entities - Oncology/Immunology & Subsidiaries) | 1159 | 1715 | 2025 | 72 | ||
| Total number of employees by contract type - Part-time (Consolidated + SHPL) | 46 | 2 | 72 | |||
| Total number of employees by contract type - Part-time (Consolidated entities - Oncology/Immunology & Subsidiaries) | 46 | 2 | 72 | |||
| Total number of employees by employee category - Executive and Senior management (Consolidated + SHPL, Female) | 8 | 6 | 10 | 72 | ||
| Total number of employees by employee category - Executive and Senior management (Consolidated + SHPL, Male) | 18 | 21 | 22 | 72 | ||
| Total number of employees by employee category - Executive and Senior management (Consolidated entities - Oncology/Immunology & Subsidiaries, Female) | 3 | 3 | 7 | 72 | ||
| Total number of employees by employee category - Executive and Senior management (Consolidated entities - Oncology/Immunology & Subsidiaries, Male) | 11 | 14 | 15 | 72 | ||
| Total number of employees by employee category - General staff (Consolidated + SHPL, Female) | 1668 | 1800 | 2114 | 72 | ||
| Total number of employees by employee category - General staff (Consolidated + SHPL, Male) | 1715 | 1757 | 1907 | 72 | ||
| Total number of employees by employee category - General staff (Consolidated entities - Oncology/Immunology & Subsidiaries, Female) | 462 | 672 | 806 | 72 | ||
| Total number of employees by employee category - General staff (Consolidated entities - Oncology/Immunology & Subsidiaries, Male) | 425 | 564 | 649 | 72 | ||
| Total number of employees by employee category - Middle management (Consolidated + SHPL, Female) | 299 | 499 | 453 | 72 | ||
| Total number of employees by employee category - Middle management (Consolidated + SHPL, Male) | 413 | 515 | 507 | 72 | ||
| Total number of employees by employee category - Middle management (Consolidated entities - Oncology/Immunology & Subsidiaries, Female) | 141 | 241 | 288 | 72 | ||
| Total number of employees by employee category - Middle management (Consolidated entities - Oncology/Immunology & Subsidiaries, Male) | 163 | 221 | 262 | 72 | ||
| Total number of employees by gender - Corporate Head Office (Female) | 25 | 28 | 34 | 71 | ||
| Total number of employees by gender - Corporate Head Office (Male) | 23 | 20 | 24 | 71 | ||
| Total number of employees by gender - Oncology/Immunology – Commercial (Female) | 237 | 299 | 410 | 71 | ||
| Total number of employees by gender - Oncology/Immunology – Commercial (Male) | 261 | 346 | 455 | 71 | ||
| Total number of employees by gender - Oncology/Immunology – R&D (Female) | 346 | 487 | 579 | 71 | ||
| Total number of employees by gender - Oncology/Immunology – R&D (Male) | 261 | 346 | 382 | 71 | ||
| Total number of employees by gender - Other Ventures (SHPL) (Female) | 1357 | 1389 | 1476 | 71 | ||
| Total number of employees by gender - Other Ventures (SHPL) (Male) | 1541 | 1494 | 1510 | 71 | ||
| Total number of employees by gender - Other Ventures (excluding non-consolidated SHPL) (Female) | 84 | 102 | 78 | 71 | ||
| Total number of employees by gender - Other Ventures (excluding non-consolidated SHPL) (Male) | 47 | 95 | 65 | 71 | ||
| Total number of employees by gender - Total (Female) | 1975 | 2293 | 2577 | 71 | ||
| Total number of employees by gender - Total (Male) | 2146 | 2050 | 2436 | 71 | ||
| Total number of employees by region - Hong Kong (Female) | 23 | 32 | 52 | 71 | ||
| Total number of employees by region - Hong Kong (Male) | 21 | 24 | 26 | 71 | ||
| Total number of employees by region - Mainland China (Female) | 555 | 808 | 969 | 71 | ||
| Total number of employees by region - Mainland China (Male) | 560 | 724 | 852 | 71 | ||
| Total number of employees by region - US, Europe and Others (Female) | 29 | 76 | 80 | 71 | ||
| Total number of employees by region - US, Europe and Others (Male) | 17 | 51 | 48 | 71 |
Employee turnover rate by gender, age group and geographical region.
| Indicator | Unit | 2020 | 2021 | 2022 | Report Pages |
|---|---|---|---|---|---|
| Employee turnover by age (%) - 20-29 - Consolidated +SHPL | % | 34 | 30 | 31 | 73 |
| Employee turnover by age (%) - 20-29 - Consolidated entities (Oncology/Immunology & Subsidiaries) | % | 20 | 26 | 34 | 73 |
| Employee turnover by age (%) - 30-39 - Consolidated +SHPL | % | 18 | 22 | 20 | 73 |
| Employee turnover by age (%) - 30-39 - Consolidated entities (Oncology/Immunology & Subsidiaries) | % | 19 | 26 | 28 | 73 |
| Employee turnover by age (%) - 40-49 - Consolidated +SHPL | % | 12 | 10 | 9 | 73 |
| Employee turnover by age (%) - 40-49 - Consolidated entities (Oncology/Immunology & Subsidiaries) | % | 21 | 14 | 18 | 73 |
| Employee turnover by age (%) - 50-59 - Consolidated +SHPL | % | 17 | 5 | 14 | 73 |
| Employee turnover by age (%) - 50-59 - Consolidated entities (Oncology/Immunology & Subsidiaries) | % | 28 | 2 | 30 | 73 |
| Employee turnover by age (%) - 60 and above - Consolidated +SHPL | % | 65 | 54 | 73 | 73 |
| Employee turnover by age (%) - 60 and above - Consolidated entities (Oncology/Immunology & Subsidiaries) | % | 13 | 10 | 40 | 73 |
| Employee turnover by region (%) - Hong Kong - Consolidated +SHPL | % | N/A | 16 | 23 | 73 |
| Employee turnover by region (%) - Hong Kong - Consolidated entities (Oncology/Immunology & Subsidiaries) | % | 9 | 16 | 23 | 73 |
| Employee turnover by region (%) - Mainland China - Consolidated +SHPL | % | N/A | 21 | 19 | 73 |
| Employee turnover by region (%) - Mainland China - Consolidated entities (Oncology/Immunology & Subsidiaries) | % | 21 | 24 | 27 | 73 |
| Employee turnover by region (%) - US, Europe and Others - Consolidated +SHPL | % | N/A | 8 | 35 | 73 |
| Employee turnover by region (%) - US, Europe and Others - Consolidated entities (Oncology/Immunology & Subsidiaries) | % | 7 | 8 | 35 | 73 |
| Employee turnover rate by gender - Female (Consolidated + SHPL) | % | 18% | 18% | 18% | 72 |
| Employee turnover rate by gender - Female (Consolidated entities - Oncology/Immunology & Subsidiaries) | % | 19% | 19% | 24% | 72 |
| Employee turnover rate by gender - Male (Consolidated + SHPL) | % | 20% | 23% | 21% | 72 |
| Employee turnover rate by gender - Male (Consolidated entities - Oncology/Immunology & Subsidiaries) | % | 20% | 27% | 32% | 72 |
| Employee turnover rate by gender - Total (Consolidated + SHPL) | % | 19% | 21% | 20% | 72 |
| Employee turnover rate by gender - Total (Consolidated entities - Oncology/Immunology & Subsidiaries) | % | 20% | 23% | 28% | 72 |
Lost days due to work injury.
| Indicator | Unit | 2020 | 2021 | 2022 | Report Pages |
|---|---|---|---|---|---|
| Lost days due to work injury - Consolidated +SHPL | Days | N/A | 64.5 | 326 | 73 |
| Lost days due to work injury - Consolidated entities (Oncology/Immunology & Subsidiaries) | Days | 45 | 73 | ||
| Lost days rate - Consolidated +SHPL | % | 6.28 | 1.4 | 6.51 | 73 |
| Lost days rate - Consolidated entities (Oncology/Immunology & Subsidiaries) | % | N/A | 2.23 | 73 |
The percentage of employees trained by gender and employee category (e.g. senior management, middle management).
| Indicator | Unit | 2020 | 2021 | 2022 | Report Pages |
|---|---|---|---|---|---|
| Percentage of employees trained by employee category - Executive and Senior management - Consolidated +SHPL | 95% | 100% | 100% | 73 | |
| Percentage of employees trained by employee category - Executive and Senior management - Consolidated entities (Oncology/Immunology & Subsidiaries) | 100% | 100% | 100% | 73 | |
| Percentage of employees trained by employee category - General staff - Consolidated +SHPL | 89% | 100% | 100% | 73 | |
| Percentage of employees trained by employee category - General staff - Consolidated entities (Oncology/Immunology & Subsidiaries) | 100% | 100% | 100% | 73 | |
| Percentage of employees trained by employee category - Middle management - Consolidated +SHPL | 93% | 100% | 100% | 73 | |
| Percentage of employees trained by employee category - Middle management - Consolidated entities (Oncology/Immunology & Subsidiaries) | 100% | 100% | 100% | 73 | |
| Percentage of employees trained by employee category - Total - Consolidated +SHPL | 94% | 100% | 100% | 73 | |
| Percentage of employees trained by employee category - Total - Consolidated entities (Oncology/Immunology & Subsidiaries) | 100% | 100% | 100% | 73 | |
| Percentage of employees trained by gender (Consolidated + SHPL - Female) | 92% | 100% | 100% | 74 | |
| Percentage of employees trained by gender (Consolidated + SHPL - Male) | 96% | 100% | 100% | 74 | |
| Percentage of employees trained by gender (Consolidated + SHPL - Total) | 94% | 100% | 100% | 74 | |
| Percentage of employees trained by gender (Consolidated entities - Female) | 100% | 100% | 100% | 74 | |
| Percentage of employees trained by gender (Consolidated entities - Male) | 100% | 100% | 100% | 74 | |
| Percentage of employees trained by gender (Consolidated entities - Total) | 100% | 100% | 100% | 74 |
The average training hours completed per employee by gender and employee category.
| Indicator | Unit | 2020 | 2021 | 2022 | Report Pages |
|---|---|---|---|---|---|
| Average training hours by employment category (Consolidated + SHPL - Executive and Senior management) | hours | 17.5 | 15.5 | 37.4 | 74 |
| Average training hours by employment category (Consolidated + SHPL - General staff) | hours | 10.6 | 21.6 | 28.2 | 74 |
| Average training hours by employment category (Consolidated + SHPL - Middle management) | hours | 18.7 | 17.7 | 37.7 | 74 |
| Average training hours by employment category (Consolidated + SHPL - Total) | hours | 17.5 | 16 | 30.1 | 74 |
| Average training hours by employment category (Consolidated entities - Executive and Senior management) | hours | 14.6 | 74 | ||
| Average training hours by employment category (Consolidated entities - General staff) | hours | 23.7 | 74 | ||
| Average training hours by employment category (Consolidated entities - Middle management) | hours | 20.8 | 74 | ||
| Average training hours by employment category (Consolidated entities - Total) | hours | 22.8 | 74 | ||
| Average training hours by gender (Consolidated + SHPL - Female) | hours | 17 | 17 | 28.3 | 74 |
| Average training hours by gender (Consolidated + SHPL - Male) | hours | 18 | 15 | 32 | 74 |
| Average training hours by gender (Consolidated + SHPL - Total) | hours | 17.5 | 16 | 30.1 | 74 |
| Average training hours by gender (Consolidated entities - Female) | hours | 22 | 74 | ||
| Average training hours by gender (Consolidated entities - Male) | hours | 23.8 | 74 | ||
| Average training hours by gender (Consolidated entities - Total) | hours | 22.8 | 74 | ||
| Total training hours (Consolidated + SHPL) | hours | 16362 | 152005 | 74 | |
| Total training hours (Consolidated entities) | hours | 47375 | 74 | ||
| Total training hours of health & safety - Consolidated +SHPL | Hours | 1341 | 4118 | 11775 | 73 |
| Total training hours of health & safety - Consolidated entities (Oncology/Immunology & Subsidiaries) | Hours | N/A | 5490 | 73 | |
| Total training hours on Anti-corruption and Compliance (Consolidated + SHPL) | hours | 12130 | 7333 | 74 | |
| Total training hours on Anti-corruption and Compliance (Consolidated entities) | hours | 2100 | 74 | ||
| Total training hours on Code of Ethics (Consolidated + SHPL) | hours | 113.5 | 532 | 74 | |
| Total training hours on Code of Ethics (Consolidated entities) | hours | 532 | 74 | ||
| Total training hours on Health and Safety (Consolidated + SHPL) | hours | 4118 | 11775 | 74 | |
| Total training hours on Health and Safety (Consolidated entities) | hours | 5490 | 74 | ||
| Total training hours on Other topics (Consolidated + SHPL) | hours | 132365 | 74 | ||
| Total training hours on Other topics (Consolidated entities) | hours | 39235 | 74 |
Number of suppliers by geographical region.
| Indicator | Unit | 2022 | Report Pages |
|---|---|---|---|
| Number of suppliers in Hong Kong | 97 | 59 | |
| Number of suppliers in Mainland China | 2803 | 59 | |
| Number of suppliers in United States and other countries | 277 | 59 | |
| Total number of suppliers | 3177 | 59 |
Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.
| Indicator | Unit | 2022 | Report Pages |
|---|---|---|---|
| stakeholder engagement management response rate | percent | 95 | 3 |
| stakeholder engagement overall response rate | percent | 44 | 3 |
| stakeholder engagement survey and sessions, number of key internal and external stakeholders | 2400 | 3 |
Number of products and service related complaints received and how they are dealt with.
| Indicator | Unit | 2022 | Report Pages |
|---|---|---|---|
| Number of batches of official samples supported | 15 | 59 |
Description of quality assurance process and recall procedures.
| Indicator | Unit | 2022 | Report Pages |
|---|---|---|---|
| Quality audit plan completion rate | 100% | 59 |
Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.
| Indicator | Unit | 2022 | Report Pages |
|---|---|---|---|
| Average number of quality audits carried out | 80 | 59 | |
| Number of regulatory inspections supported | 10 | 59 |
Resources contributed (e.g. money or time) to the focus area.
| Indicator | Unit | 2020 | 2021 | 2022 | Report Pages |
|---|---|---|---|---|---|
| Revenue (Consolidated + SHPL) | US$'000 | 797009 | 40 | ||
| Revenue (Consolidated Entities - Oncology/Immunology & Subsidiaries) | US$'000 | 426409 | 40 | ||
| Revenue (consolidated entities) - Consolidated +SHPL | US$'000 | 481669 | 667036 | 797009 | 44 |
| Revenue (consolidated entities) - Consolidated Entities (Oncology/Immunology & Subsidiaries) | US$'000 | 205315 | 334388 | 426409 | 44 |
The types of emissions and respective emissions data.
| Standard Indicator | Unit | 2021 | 2022 |
|---|---|---|---|
| Airborne Particulate Matter (PM) Emissions | kg | 155.4 | 130.23 |
| NOâ‚“ Emissions | kg | 889.38 | 843.86 |
| SOâ‚“ Emissions | kg | 0.57 | 0.56 |
Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).
| Standard Indicator | Unit | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Direct GHG Emissions (Scope 1) | tCO2e | 6040 | 5169 | 5587 | |
| Indirect Energy Emissions (Scope 2) | tCO2e | 19506 | 16336 | 14519 | |
| Scope 3 GHG Emissions (Business Travel) | kg CO2e | 364542 | 261719 | 522348 | 381919 |
| Total GHG Emissions | tCO2e | 21946 | 21505 | 20106 | |
| Total GHG Emissions Intensity (By Employee) | tCO2e per employee | 4.01 | |||
| Total GHG Emissions Intensity (By Revenue) | tCO2e/US$'000 | 0.046 | 0.032 | 0.025 | |
| Total Other Indirect Energy Emissions (Scope 3) | tCO2e | 410 | 721 | 442 |
Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).
| Standard Indicator | Unit | 2021 | 2022 |
|---|---|---|---|
| Total Hazardous Waste | tons | 113 | 137 |
| Total Hazardous Waste Intensity (By Revenue) | tons/US$'000 revenue | 0.000193 | 0.000172 |
Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).
| Standard Indicator | Unit | 2021 | 2022 |
|---|---|---|---|
| Total Non-Hazardous Waste Intensity (By Revenue) | tons/US$'000 revenue | 0.000184 | 0.00042 |
Description of emissions target(s) set and steps taken to achieve them.
| Standard Indicator | Unit | 2022 |
|---|---|---|
| Percentage of Reduction in GHG Intensity Compared to Last Year | percent | 48 |
Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.
| Standard Indicator | Unit | 2022 |
|---|---|---|
| Plastic Waste Reduction Compared to Last Year | tons | -86 |
| Plastic Waste Reduction Percentage Compared to Last Year | % | -81.13 |
Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).
| Standard Indicator | Unit | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Diesel Fuel Consumption | GJ | 2 | 2 | |
| Energy Consumption Intensity (By Revenue) | GJ per US$'000 revenue | 0.128 | 0.338 | 0.289 |
| Gasoline Consumption | GJ | 182 | 1067 | 911 |
| Natural Gas Consumption | GJ | 124587 | 140942 | |
| Purchased Electricity | GJ | 26025 | 99883 | 88810 |
| Purchased Steam | GJ | 11 | 11 | 10 |
| Total Energy Consumption | GJ | 26014 | 225549 | 230674 |
Water consumption in total and intensity (e.g. per unit of production volume, per facility).
| Standard Indicator | Unit | 2021 | 2022 |
|---|---|---|---|
| Total Wastewater Discharge | cubic meters | 223534 | 189064 |
| Water Consumption | cubic meters | 311256 | 270555 |
| Water Consumption Intensity (By Revenue) | cubic meters/US$'000 revenue | 0.47 | 0.34 |
Description of energy use efficiency target(s) set and steps taken to achieve them.
| Standard Indicator | Unit | 2022 | 2025 |
|---|---|---|---|
| Energy Consumption Reduction Percentage Compared to Last Year | percent | 40 | |
| Target Energy Consumption Reduction Percentage Compared to Last Year | percent | 10 |
Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.
| Standard Indicator | Unit | 2022 |
|---|---|---|
| Water Consumption Reduction Percentage Compared to Last Year | % | 13 |
Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.
| Standard Indicator | Unit | 2021 | 2022 |
|---|---|---|---|
| Packaging Material Consumption (Metal) | tons | 35 | 36 |
| Packaging Material Consumption (Paper) | tons | 1106 | 750 |
| Packaging Material Consumption (Plastic) | tons | 779 | 830 |
| Packaging Materials Consumed | tons | 1920 | 1616 |
Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.
| Standard Indicator | Unit | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Number of Employees Aged 30-50 | person | 2865 | 2344 | 1908 |
| Number of Employees Aged 30-50 (Female) | person | 945 | 611 | 1238 |
| Number of Employees Aged 30-50 (Male) | person | 1920 | 1733 | 670 |
| Number of Employees Aged Above 50 | person | 154 | 110 | 112 |
| Number of Employees Aged Above 50 (Female) | person | 68 | 54 | 59 |
| Number of Employees Aged Above 50 (Male) | person | 86 | 56 | 53 |
| Number of Employees Aged Below 30 | person | 658 | 312 | 507 |
| Number of Employees Aged Below 30 (Female) | person | 88 | 160 | 304 |
| Number of Employees Aged Below 30 (Male) | person | 570 | 152 | 203 |
| Number of Employees in Hong Kong | person | 44 | 56 | 78 |
| Number of Employees in Hong Kong (Female) | person | 23 | 32 | 52 |
| Number of Employees in Hong Kong (Male) | person | 21 | 24 | 26 |
| Number of Employees in Mainland China | person | 1115 | 1532 | 1821 |
| Number of Employees in Mainland China (Female) | person | 555 | 808 | 969 |
| Number of Employees in Mainland China (Male) | person | 560 | 724 | 852 |
| Number of Employees in Overseas | person | 46 | 127 | 128 |
| Number of Employees in Overseas (Female) | person | 29 | 76 | 80 |
| Number of Employees in Overseas (Male) | person | 17 | 51 | 48 |
| Number of Female Employees | person | 1975 | 2293 | 2577 |
| Number of Full-time Employees | person | 4075 | 4598 | 5011 |
| Number of General Employees (Female) | person | 1668 | 1800 | 2114 |
| Number of General Employees(Male) | person | 1715 | 1757 | 1907 |
| Number of Male Employees | person | 2146 | 2050 | 2436 |
| Number of Middle Management Employees (Female) | person | 299 | 499 | 453 |
| Number of Middle Management Employees (Male) | person | 413 | 515 | 507 |
| Number of Part-time Employees | person | 46 | 2 | |
| Number of Senior Management Employees (Female) | person | 8 | 6 | 10 |
| Number of Senior Management Employees (Male) | person | 18 | 21 | 22 |
| Number of Total Employees | person | 4121 | 4598 | 5013 |
| Percentage of Female Employees | percent | 47.92 | 49.87 | 51.4 |
| Percentage of Full-time Employees | percent | 98.88 | 100 | 99.96 |
| Percentage of Male Employees | percent | 52.08 | 44.6 | 48.6 |
| Percentage of Part-time Employees | percent | 1.12 | 0.04 |
Employee turnover rate by gender, age group and geographical region.
| Standard Indicator | Unit | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Turnover Rate of Employees Aged 30-50 | % | 18 | 22 | 20 |
| Turnover Rate of Employees Aged Above 50 | % | 65 | 54 | 73 |
| Turnover Rate of Employees Aged Below 30 | % | 34 | 30 | 31 |
| Turnover Rate of Employees in Hong Kong | % | 9 | 16 | 23 |
| Turnover Rate of Employees in Mainland China | % | 21 | 21 | 19 |
| Turnover Rate of Employees in Overseas | % | 7 | 8 | 35 |
| Turnover Rate of Female Employees | % | 18 | 18 | 18 |
| Turnover Rate of Male Employees | % | 20 | 23 | 21 |
| Turnover Rate of Total Employees | % | 19 | 21 | 20 |
Lost days due to work injury.
| Standard Indicator | Unit | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Lost Days Due to Work-related Injuries | Days | 64.5 | 326 | |
| Rate of Work-related Injuries | % | 6.28 | 1.4 | 6.51 |
The percentage of employees trained by gender and employee category (e.g. senior management, middle management).
| Standard Indicator | Unit | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Percentage of Employees Trained | % | 94 | 100 | 100 |
| Percentage of Trained Female Employees | % | 92 | 100 | 100 |
| Percentage of Trained General Employees | % | 89 | 100 | 100 |
| Percentage of Trained Male Employees | % | 96 | 100 | 100 |
| Percentage of Trained Middle Management | % | 93 | 100 | 100 |
| Percentage of Trained Senior Management | % | 95 | 100 | 100 |
The average training hours completed per employee by gender and employee category.
| Standard Indicator | Unit | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Average Training Hours (Female) | hours | 17 | 17 | 28.3 |
| Average Training Hours (General Staff) | hours | 10.6 | 21.6 | 28.2 |
| Average Training Hours (Male) | hours | 18 | 15 | 32 |
| Average Training Hours (Middle Management) | hours | 18.7 | 17.7 | 37.7 |
| Average Training Hours (Senior Management) | hours | 17.5 | 15.5 | 37.4 |
| Average Training Hours per Employee | hours | 17.5 | 16 | 30.1 |
| Total Training Hours | hours | None | 16362 | 152005 |
| Training Hours of Anti-corruption | hours | 12130 | 7333 |
Number of suppliers by geographical region.
| Standard Indicator | Unit | 2022 |
|---|---|---|
| Number of Suppliers in Hong Kong | 97 | |
| Number of Suppliers in Mainland China | 2803 | |
| Number of Total Suppliers | 3177 |